Cefoxitin Continuous Infusion for Lung Infection Caused by the Mycobacterium abscessus Group
暂无分享,去创建一个
D. Curran‐Everett | M. Moridani | P. Anderson | C. Czaja | A. Levin | Jessica Krank | D. Curran-Everett
[1] John D. Mitchell,et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] R. Wallace,,et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .
[3] M. Rowland,et al. Clinical pharmacokinetics and pharmacodynamics , 2011 .
[4] Mary Ann Blosky,et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. , 2010, American journal of respiratory and critical care medicine.
[5] Young Kil Park,et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. , 2009, American journal of respiratory and critical care medicine.
[6] D. Paterson,et al. A systematic review on clinical benefits of continuous administration of &bgr;-lactam antibiotics* , 2009, Critical care medicine.
[7] Robert Horsburgh,et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.
[8] M. Falagas,et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. , 2005, The Lancet. Infectious diseases.
[9] W. Adams,et al. Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination , 1989, Antimicrobial Agents and Chemotherapy.
[10] Malcolm Rowland,et al. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications , 1980 .